STAMFORD, CT- April 13, 2015- ArisGlobal, a leading provider of solutions to the life sciences industry, has today announced the availability of agFileMaster; a Cloud-based electronic trial master file (eTMF) solution that serves as a centralized, global repository for managing all clinical trial-related documents in accordance with GCP standards and applicable regulatory requirements.
agFileMaster can be deployed either as a stand-alone solution or unified as part of ArisGlobal’s Clinical Trial Management System (CTMS). Life science organizations can overcome the complex burden of collecting, organizing and tracking the vast amount of essential trial documents from a multitude of disparate content management repositories with a single solution that provides real-time, controlled access to essential trial documentation.
Fully validated, agFileMaster supports the DIA TMF Reference model and is 21 CFR Part 11 compliant, helping to ensure the TMF file structure and organization is ready for audit and inspection. Full, context-sensitive document management capabilities and integrated workflows support and streamline key business processes to speed up site set-up and initiation and ensure patient recruitment can start as early as possible.
“Many of today’s current eTMF solutions are falling short of what is needed,” said Simon Sparkes, Executive Vice President, Product Strategy at ArisGlobal. “We need to be able to more than just organize documents. A modern eTMF needs to be able to identify documents required for each country and entity, identifing missing documents while allowing online exchange with sites. Ultimately, the aim of any eTMF is to support a submission/approval process. Our eTMF fully supports the tracking of all documents required for approval as well as tracking the submission itself. Of course an eTMF becomes truly effective when integrated with a CTMS. agFileMaster goes beyond the limitations of traditional integration of incompatible vendor solutions and is part of our fully unified clinical operations platform including agClinical CTMS ”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.